Sir, Was it God who had meant mere mortals to forget and ignore the parathyroid glands or was it Nature who thought that humans would never understand the importance of these glands and hence decided to conceal them behind a much larger endocrine organ, the thyroid? However, in this age of evidence-based medicine, can we still continue to ignore these little dot-like structures?
It is difficult to definitely pinpoint the prevalence of hypoparathyroidism in our country because of the lack of published research in this field, but data from Denmark put an incidence of 0.8 per 1 lakh person-years and a prevalence of 22 per 1 lakh person-years with a somewhat higher prevalence in the USA (37 per lakh). [1] To manifest clinically, all the parathyroid glands (commonly four in number) need to stop functioning and hence hypoparathyroidism is quite uncommon. Even then, the myriad clinical manifestations range from renal calculi, posterior subcapsular cataract to seizures. The most fascinating manifestations are, however, the ones involving the nervous system. Imaging studies have noted the presence of calcifications in the brain as well as calculi in the kidneys. Unfortunately, however, there is not much correlation between the severities of the clinical manifestations with the radiological extent of the disease. [2] Neurological manifestations have been reported since as long back as 1967 where they documented patients manifesting with tetany, chorea, and seizures. [3] Some very relevant publications from India have found carpopedal spasm as the most common clinical manifestation of hypoparathyroidism (about 70% cases), followed by paresthesia and seizures (54%). [2] More specifically, the most common clinical manifestation of hypoparathyroidism seems to be neurological. [3] We too have been seeing hypoparathyroidism manifest with different neurological manifestations. We have found patients to present with varied extrapyramidal symptoms such as choreoathetosis and status epilepticus. [4] We have also noted patients to present with clinical manifestations of the cerebellar disease. [5] As such, the primary interaction with the patient should focus on trying to elicit signs and symptoms of neuromuscular irritability, [2] out of which the most common (as noted above) is paresthesias (involving fingertips, toes, perioral area), followed by others such as hyperirritability, fatigue, anxiety, mood swings and/or personality disturbances, seizures (especially in patients with epilepsy), hoarseness (due to laryngospasm), wheezing and dyspnea (due to bronchospasm), muscle cramps, diaphoresis, and biliary colic. [6] Often this neuromuscular irritability may just manifest as cramps in the legs, feet, and back. It is only when the irritability is more that we get the clinical signs of Chvostek and Trousseau. Choreoathetoid movements, as documented in our patient, have also been reported by other clinicians and are probably due to the basal ganglia calcifications that we see in primary hypoparathyroidism. [7] Even features of Parkinsonism, dystonias, hemiballismus, and oculogyric crises have been noted by clinicians to the extent of up to 5% cases of idiopathic hypoparathyroidism. [8] Ataxia, paraplegia, dysphagia, and dysarthria have all been documented in patients with hypoparathyroidism. Thankfully, there are some symptoms which have been seen to get reverted with correction of the hypocalcemia starting from Chvostek and Trousseau signs to papilledema. Many patients primarily present to psychiatrists with features of emotional instability, anxiety, depression, confusion, hallucinations, and psychosis. Thankfully, normocalcemia corrects these conditions. [6] To make matters worse, any coexisting hypomagnesemia, hypokalemia, and alkalosis will worsen the signs and symptoms of hypocalcemia and hence needs to be excluded while treating a patient with hypoparathyroidism.
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Letters 
On the Therapy for Polycystic Ovary Syndrome
Sir, We have read with great attention the article titled, "The inositols and polycystic ovary syndrome" by Kalra et al. [1] The authors have correctly outlined the physiological activities of the two most important stereoisomers of inositol, myoinositol (MI), and D-chiro-inositol (DCI). We provide a more accurate analysis of these data, which will help ensure pragmatic prescription of these useful molecules.
Kalra et al. stated, "the correction of systemic insulin resistance by MI will treat the metabolic features of polycystic ovary syndrome (PCOS). Simultaneously, adequate DCI levels will create a healthy intraovarian milieu, which will correct hyperandrogenism, improve menstrual regularity, and promote ovulation and fertility. …While MI is necessary for metabolic management, DCI is equally important for menstrual, ovulatory, and cutaneous hyperandrogenic resolution. …A high concentration of DCI is necessary to circumvent epimerase deficiency and ensure adequate levels in the ovary. Most pharmaceutical preparations provide very low amounts of DCI which are insufficient to achieve adequate levels in the ovary. Hence, formulations with relatively higher levels of DCI are preferred."
Recent scientific data, however, suggest otherwise. [2, 3] Of the two stereoisomers, MI stands out for its important biological roles as a leading molecule, whereas different integrative functions are carried out by DCI. In particular, whereas the activation of glucose transporters and glucose utilization take place under the regulation of MI, glycogen synthesis is mainly controlled through DCI. On the other hand, in the ovary, MI regulates glucose uptake and follicle-stimulating hormone (FSH) signaling, while DCI modulates insulin-induced androgen synthesis. [2, 3] In physiological conditions, the intracellular pool of inositol in human ovaries contains 99% of MI, whereas the remaining part is DCI. [4] In the ovary of PCOS women, we find an imbalance between MI and DCI concentrations, with a putative MI deficiency, which might impair the FSH signaling. [4] In these conditions, glucose uptake and metabolism of both oocytes and follicular cells are negatively affected compromising oocyte quality that depends on MI levels. [3] The improvement of ovarian function, as well as hormonal and metabolic parameters, was demonstrated after MI treatment in PCOS women. [5] Moreover, comparing the effects of metformin and MI on restored spontaneous ovulation activity in PCOS patients, the treated group showed better results for healed patients' number and recovery time. [3] Finally, high doses of DCI alone, administered to PCOS subjects, were found significantly detrimental for oocytes and therefore for fertility. [3] Last but not least, MI is a well-established safe molecule, [6] whereas the data are lacking for DCI. In conclusion, therapeutically, DCI plays a relevant function at systemic, and not local, level in the metabolic syndromes, where its administration can improve insulin sensitivity and reduce serum free testosterone levels compared to placebo group. However, at elevated doses, it is harmful in PCOS patients. On the other hand, MI exerts positive effects both at systemic and local (ovary) level.
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